enVVeno Medical (NASDAQ:NVNO) Issues Quarterly Earnings Results, Misses Expectations By $3.02 EPS

enVVeno Medical (NASDAQ:NVNO) released its earnings results on Thursday. The company reported ($6.29) EPS for the quarter, missing analysts’ consensus estimates of ($3.27) by ($3.02), FiscalAI reports.

enVVeno Medical Stock Performance

Shares of NVNO stock traded up $0.28 on Thursday, reaching $7.02. 14,439 shares of the stock were exchanged, compared to its average volume of 40,021. The business’s 50 day moving average price is $9.11 and its 200 day moving average price is $10.38. enVVeno Medical has a twelve month low of $6.52 and a twelve month high of $25.90.

Analyst Ratings Changes

A number of brokerages recently weighed in on NVNO. Weiss Ratings restated a “sell (e+)” rating on shares of enVVeno Medical in a research note on Friday, September 25th. Zacks Research upgraded enVVeno Medical to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen upgraded enVVeno Medical to a “hold” rating in a research note on Saturday, October 24th. Finally, LADENBURG THALM/SH SH upgraded shares of enVVeno Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold”.

About enVVeno Medical

enVVeno Medical Corporation (NASDAQ:NVNO) is a late-stage medical device company focused on developing bioprosthetic, or tissue-based, treatments for venous disease. Its primary focus is chronic venous insufficiency, a condition in which damaged or absent valves allow blood to flow backward in the veins and can cause swelling, pain, skin changes and ulcers.

The company’s lead product is the VenoValve, a surgically implanted bioprosthetic valve designed to restore one-way blood flow in the deep veins of the leg.